155 related articles for article (PubMed ID: 12821497)
1. Intra- and interindividual variabilities of valacyclovir oral bioavailability and effect of coadministration of an hPEPT1 inhibitor.
Phan DD; Chin-Hong P; Lin ET; Anderle P; Sadee W; Guglielmo BJ
Antimicrob Agents Chemother; 2003 Jul; 47(7):2351-3. PubMed ID: 12821497
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of acyclovir in the cat.
Owens JG; Nasisse MP; Tadepalli SM; Dorman DC
J Vet Pharmacol Ther; 1996 Dec; 19(6):488-90. PubMed ID: 8971679
[No Abstract] [Full Text] [Related]
3. Effect of ionization on the variable uptake of valacyclovir via the human intestinal peptide transporter (hPepT1) in CHO cells.
Balimane P; Sinko P
Biopharm Drug Dispos; 2000 Jul; 21(5):165-74. PubMed ID: 11180195
[TBL] [Abstract][Full Text] [Related]
4. MDR1 genotypes do not influence the absorption of a single oral dose of 600 mg valacyclovir in healthy Chinese Han ethnic males.
Zhang Y; Jiang XH; Hu YQ; Li ZR; Su L; Wang ZG; Ma G
Br J Clin Pharmacol; 2008 Aug; 66(2):247-54. PubMed ID: 18460034
[TBL] [Abstract][Full Text] [Related]
5. A physiologically based pharmacokinetic model for valacyclovir established based on absolute expression quantity of hPEPT1 and its application.
Sun L; Wang C; Zhang Y
Eur J Pharm Sci; 2018 Oct; 123():560-568. PubMed ID: 30081070
[TBL] [Abstract][Full Text] [Related]
6. Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice.
Yang B; Smith DE
Drug Metab Dispos; 2013 Mar; 41(3):608-14. PubMed ID: 23264448
[TBL] [Abstract][Full Text] [Related]
7. Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir.
Lycke J; Malmeström C; Ståhle L
Antimicrob Agents Chemother; 2003 Aug; 47(8):2438-41. PubMed ID: 12878501
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses.
Garré B; Shebany K; Gryspeerdt A; Baert K; van der Meulen K; Nauwynck H; Deprez P; De Backer P; Croubels S
Antimicrob Agents Chemother; 2007 Dec; 51(12):4308-14. PubMed ID: 17846132
[TBL] [Abstract][Full Text] [Related]
9. In Silico Absorption Analysis of Valacyclovir in Wildtype and Pept1 Knockout Mice Following Oral Dose Escalation.
Yang B; Smith DE
Pharm Res; 2017 Nov; 34(11):2349-2361. PubMed ID: 28770489
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir.
Zeng L; Nath CE; Blair EY; Shaw PJ; Stephen K; Earl JW; Coakley JC; McLachlan AJ
Antimicrob Agents Chemother; 2009 Jul; 53(7):2918-27. PubMed ID: 19414579
[TBL] [Abstract][Full Text] [Related]
11. Multiple oral dosing of valacyclovir in horses and ponies.
Garré B; Baert K; Nauwynck H; Deprez P; De Backer P; Croubels S
J Vet Pharmacol Ther; 2009 Jun; 32(3):207-12. PubMed ID: 19646083
[TBL] [Abstract][Full Text] [Related]
12. Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter.
Han HK; Oh DM; Amidon GL
Pharm Res; 1998 Sep; 15(9):1382-6. PubMed ID: 9755889
[TBL] [Abstract][Full Text] [Related]
13. Bioequivalence studies of two different film-coated tablet formulations of valacyclovir of two different strengths in healthy volunteers.
Neves R; Almeida S; Filipe A; Spinola AC; Abolfathi Z; Lévesque A; Ortuño J; Torns A
Arzneimittelforschung; 2010; 60(5):273-81. PubMed ID: 20533765
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of acyclovir in immunocompromized children with leukopenia and mucositis after chemotherapy: can intravenous acyclovir be substituted by oral valacyclovir?
Eksborg S; Pal N; Kalin M; Palm C; Söderhäll S
Med Pediatr Oncol; 2002 Apr; 38(4):240-6. PubMed ID: 11920787
[TBL] [Abstract][Full Text] [Related]
15. Valacyclovir for herpes simplex encephalitis.
Pouplin T; Pouplin JN; Van Toi P; Lindegardh N; Rogier van Doorn H; Hien TT; Farrar J; Török ME; Chau TT
Antimicrob Agents Chemother; 2011 Jul; 55(7):3624-6. PubMed ID: 21576427
[TBL] [Abstract][Full Text] [Related]
16. Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and val-valacyclovir following systemic administration in rabbits: An evaluation using ocular microdialysis and LC-MS.
Dias C; Nashed Y; Atluri H; Mitra A
Curr Eye Res; 2002 Oct; 25(4):243-52. PubMed ID: 12658558
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and bioequivalence study of valacyclovir hydrochloride capsules after single dose administration in healthy Chinese male volunteers.
Lin H; Tian Y; Tian JX; Zhang ZJ; Mao GG
Arzneimittelforschung; 2010; 60(3):162-7. PubMed ID: 20422949
[TBL] [Abstract][Full Text] [Related]
18. Impact of peptide transporter 1 on the intestinal absorption and pharmacokinetics of valacyclovir after oral dose escalation in wild-type and PepT1 knockout mice.
Yang B; Hu Y; Smith DE
Drug Metab Dispos; 2013 Oct; 41(10):1867-74. PubMed ID: 23924683
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the oligopeptide transporter, PEPT-1, in DSS-induced rat colitis.
Radeva G; Buyse M; Hindlet P; Beaufils B; Walker F; Bado A; Farinotti R
Dig Dis Sci; 2007 Jul; 52(7):1653-61. PubMed ID: 17372819
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of valacyclovir in the adult horse.
Maxwell LK; Bentz BG; Bourne DW; Erkert RS
J Vet Pharmacol Ther; 2008 Aug; 31(4):312-20. PubMed ID: 18638291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
